Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL.
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Eva Kimby Geir Erland Tjønnfjord Aaron Polliack Jan Walewski Christian Geisler |
| Publication date | April 15, 2014 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |